EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY-NC-ND 4.0

Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules

Luz E Castellanos iD, Julian Bryan iD, Julio C Ricarte-Filho iD, Aime T Franco iD, Mohammed Alshalalfa, Joshua P Klopper iD, Richard T Kloos iD, Steven G Waguespack iD

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgag059 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Luz E Castellanos und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Hauptthemen laut MEDLINE: Thyroid Nodule, Thyroid Neoplasms, Pathology, Molecular. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The Afirma Genomic Sequencing Classifier (GSC) is validated in patients ≥ 21 years with a 96% negative predictive value for malignancy when GSC-(B)enign. Afirma GSC has not been formally studied in patients <21 years of age with indeterminate thyroid nodules (ITNs).

Objective

To evaluate Afirma GSC in young patients with ITNs.

Design

Retrospective analysis of Afirma GSC testing.

Setting

ITNs referred for molecular testing in a real-world setting Participants Forty-nine ITNs from 49 patients < 21 years of age who had histopathology or 2 years' clinical follow-up data ascertained.

Intervention

None. Main outcome measure Afirma GSC test performance Results In 49 ITNs from patients aged 9 to 20 years (median 18.5 [interquartile range, 17.3-19.8]), 30 were GSC-B and 19 GSC-(S)uspicious, among which 14 (73.7%) were malignant (ie, true positive) and 5 (26.3%) were benign (ie, false positive). All 30 Afirma GSC-B cases were either histologically (n = 9) or clinically benign (n = 21) (ie, true negative). All 14 malignancies were GSC-S (sensitivity 100% [95% CI, 77-100]); 30/35 clinically or histologically benign cases were GSC-B (specificity 86% [95% CI, 70-95]). Negative predictive value for an Afirma GSC-B result was 100% [95% CI, 88-100]. Genomic alterations were not detected in the 30 GSC-B samples. Among the 14 malignant samples, there were 9 papillary thyroid carcinomas, 1 oncocytic carcinoma, 1 noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and 3 follicular thyroid carcinomas.

Conclusion

In young patients with ITNs, the Afirma GSC demonstrated an excellent negative predictive value when defining a thyroid nodule result by histology or clinical follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NoduleThyroid NeoplasmsPathology, MolecularRetrospective StudiesGenetic TestingGenomicsPredictive Value of TestsBiopsy, Fine-NeedleHumansMaleFemaleChildAdolescentYoung Adult

Stichwörter der Autor:innen

Xpression atlasbenignfusionmolecular diagnosticspediatricsuspicious

Autor:innen und Institutionen

  • Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Molecular Diagnostics Laboratory, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Division of Endocrinology and Diabetes, The Thyroid Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  • Veracyte, Inc., South San Francisco, CA 94080, USA.

ORCID-Profile: Luz E Castellanos, Julian Bryan, Julio C Ricarte-Filho, Aime T Franco, Joshua P Klopper, Richard T Kloos, Steven G Waguespack

Zitieren

APA

Castellanos, L. E., Bryan, J., Ricarte-Filho, J. C., Franco, A. T., Alshalalfa, M., Klopper, J. P., Kloos, R. T., & Waguespack, S. G. (2026). Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag059

Vancouver

Castellanos LE, Bryan J, Ricarte-Filho JC, Franco AT, Alshalalfa M, Klopper JP, et al. Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgag059

BibTeX
@article{Castellanos2026,
  author = {Castellanos, Luz E and Bryan, Julian and Ricarte-Filho, Julio C and Franco, Aime T and Alshalalfa, Mohammed and Klopper, Joshua P and Kloos, Richard T and Waguespack, Steven G},
  title = {Afirma genomic sequencing classifier performance in young patients with cytologically indeterminate thyroid nodules},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgag059}
}
Kostenlos starten →